Menu
Search
|

Menu

Close
X

Cue Biopharma Inc CUE.OQ (NASDAQ Stock Exchange Capital Market)

8.80 USD
+0.00 (+0.00%)
As of Sep 18
Previous Close 8.80
Open 9.29
Volume 45,619
3m Avg Volume 23,369
Today’s High 9.29
Today’s Low 8.73
52 Week High 9.90
52 Week Low 4.16
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
1
FY17
0
FY16
0
EPS (USD)
FY19
-1.001
FY18
-1.935
FY17
-1.440
FY16
-0.292
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Daniel Passeri
President, Chief Executive Officer, Since
Salary: --
Bonus: --
Kerri-Ann Millar
Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Rodolfo Chaparro
Executive Vice President - Head of Immunology, Since
Salary: --
Bonus: --
Ronald Seidel
Executive Vice President - Head of Research and Development, Since
Salary: --
Bonus: --
Colin Sandercock
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

21 Erie St
CAMBRIDGE   MA   02139-4260

Phone: +1617.9492680

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

SPONSORED STORIES